Novem Group Has $7.20 Million Position in Merck & Co., Inc. $MRK

Key Points

• Novem Group increased its Merck stake by 16.1% in the second quarter, bringing its holdings to 56,016 shares valued at approximately $7.20 million. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Merck reported quarterly revenue of $16.61 billion, exceeding expectations and rising 5.1% year over year, while also beating consensus EPS estimates. The company declared a quarterly dividend of $0.85, equivalent to a 2.5% annual yield.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $135.50, although recent insider selling and Merck’s dependence on Keytruda remain risks investors are monitoring.

Novem Group lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 16.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 56,016 shares of the company's stock after purchasing an additional 7,788 shares during the period. Merck & Co., Inc. accounts for about 0.7% of Novem Group's portfolio, making the stock its 25th largest position. Novem Group's holdings in Merck & Co., Inc. were worth $7,198,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CV Advisors LLC bought a new position in shares of Merck & Co., Inc. in the second quarter valued at about $1,285,000. Summitry LLC lifted its position in Merck & Co., Inc. by 6.6% during the 2nd quarter. Summitry LLC now owns 6,279 shares of the company's stock worth $807,000 after buying an additional 389 shares in the last quarter. Catalyst Private Wealth LLC bought a new stake in Merck & Co., Inc. during the 2nd quarter worth about $363,000. Clear Trail Advisors LLC grew its holdings in Merck & Co., Inc. by 0.4% during the 2nd quarter. Clear Trail Advisors LLC now owns 71,003 shares of the company's stock worth $9,124,000 after acquiring an additional 303 shares during the last quarter. Finally, Leavell Investment Management Inc. increased its position in Merck & Co., Inc. by 1.4% in the 2nd quarter. Leavell Investment Management Inc. now owns 41,794 shares of the company's stock valued at $5,406,000 after acquiring an additional 593 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 0.2%

Shares of NYSE:MRK opened at $135.78 on Friday. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.97. The company has a quick ratio of 1.06, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company's fifty day simple moving average is $125.54 and its 200 day simple moving average is $119.94. The firm has a market cap of $334.98 billion, a price-to-earnings ratio of 108.62, a PEG ratio of 5.85 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm's revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is 272.00%.

Insider Buying and Selling

In other news, EVP David Michael Williams sold 52,847 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company's stock, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares of the company's stock, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MRK shares. Wall Street Zen downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. Weiss Ratings cut shares of Merck & Co., Inc. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday. Barclays raised their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Cantor Fitzgerald restated a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Morgan Stanley upped their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a research report on Thursday, July 9th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $135.50.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source